Who are Brukinsa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Calquence, Hernexeos, Wayrilz, Itovebi, Romvimza, Itovebi.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bgb-3111.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Brukinsa — Competitive Intelligence Brief

Brukinsa (BGB-3111) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Tyrosine-protein kinase BTK Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Brukinsa (BGB-3111) — Beigene Usa Inc. Brukinsa blocks the BTK protein, which is involved in the activation of B cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brukinsa TARGET	BGB-3111	Beigene Usa Inc	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Calquence	ACALABRUTINIB	AstraZeneca	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2017-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	inavolisib	Pfizer	marketed	Kinase Inhibitor [EPC]	phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)	2024-01-01

Recent regulatory actions (last 90 days)

2026-02-26 — Hernexeos · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-04-22 — Brukinsa · 10570139 · US
2034-04-22 — Brukinsa · 11142528 · US
2034-04-22 — Brukinsa · 9447106 · US
2037-08-15 — Brukinsa · 11591340 · US
2037-08-15 — Brukinsa · 10927117 · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brukinsa — Competitive Intelligence Brief. https://druglandscape.com/ci/bgb-3111. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab